Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Analysts at Wedbush lifted their Q1 2025 earnings per share estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Monday, March 10th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($0.14) per share for the quarter, up from their previous estimate of ($0.20). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at $0.48 EPS, Q4 2025 earnings at $0.61 EPS and FY2026 earnings at $3.18 EPS.
Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.
Fennec Pharmaceuticals Stock Performance
TSE FRX opened at C$9.12 on Thursday. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market capitalization of C$175.88 million, a PE ratio of -154.49 and a beta of 0.25. The business’s 50-day moving average price is C$9.20 and its 200 day moving average price is C$7.92. Fennec Pharmaceuticals has a twelve month low of C$5.65 and a twelve month high of C$15.20.
Insider Buying and Selling at Fennec Pharmaceuticals
In other news, Director Rostislav Christov Raykov purchased 25,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was bought at an average cost of C$3.87 per share, for a total transaction of C$96,840.00. Insiders have sold a total of 21,186 shares of company stock worth $196,017 in the last quarter. 16.20% of the stock is owned by insiders.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Stories
- Five stocks we like better than Fennec Pharmaceuticals
- How to Use the MarketBeat Stock Screener
- 3 Undervalued Stocks You Can Buy at a Discount Now
- How to Capture the Benefits of Dividend Increases
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
